// App-Quantinova.ai

Sa1203 : Pharmacokinetics and Exposure-Response Relationship of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase2/3 Induction and Maintenance Studies

Researchers

Presenter

  • Zhenhua Xu

Principal Investigators

  • Colleen W. Marano

  • Brian G. Feagan

  • Paul J. Rutgeerts

  • William Sandborn

  • Richard Strauss

  • Hongyan Zhang

  • Jewel Johanns

  • Joyce A. Ford

  • Honghui Zhou

  • Hugh M. Davis

  • Jean-Frederic Colombel

  • Walter Reinisch

Medical Centers

  • Universitatsklinik fur Innere Medizin IV, Austria

  • University Hospital Gasthuisberg, Leuven, Belgium

  • University of California, San Diego, La Jolla, CA

  • Robarts Reserach Institute, London, ON, Canada

  • CHRU, Lille, France

Locations

  • Canada

  • Austria

  • United States

  • France

  • Belgium

Companies

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • golimumab

Outcome

  • N/A

Study Design

  • randomized

  • pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved